Larimar Therapeutics has been granted a patent for a fusion protein designed to treat non-nuclear organelle associated disorders like Friedrich’s Ataxia. The protein includes a cell penetrating peptide and a target enhancing sequence to deliver the protein of interest effectively. GlobalData’s report on Larimar Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Larimar Therapeutics Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Larimar Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Larimar Therapeutics's grant share as of February 2024 was 29%. Grant share is based on the ratio of number of grants to total number of patents.

Fusion protein for treating non-nuclear organelle associated disorders

Source: United States Patent and Trademark Office (USPTO). Credit: Larimar Therapeutics Inc

A recently granted patent (Publication Number: US11891420B2) discloses a fusion protein designed for delivering a protein of interest to a cell. The fusion protein comprises a cell-penetrating peptide (CPP) and a target enhancing sequence (TES), along with specific amino acid sequences that have high sequence identity to specific sequences listed in the patent. The patent claims cover various configurations of the fusion protein, including specific amino acid sequences and compositions.

Furthermore, the patent also includes claims related to the use of the fusion protein in various applications, such as intracellular delivery of proteins to non-nuclear organelles, methods for delivering proteins of interest to cells, and treating non-nuclear organelle-associated disorders like Friedreich's ataxia (PDRA). The patent also extends to the inclusion of the fusion protein in pharmaceutical compositions and its application in treating disorders in human subjects. Overall, the patent provides a comprehensive protection for the fusion protein and its use in various therapeutic and research applications.

To know more about GlobalData’s detailed insights on Larimar Therapeutics, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies